まとめ
サメの軟骨には,新しい血管の形成を制限することによって腫瘍の成長を抑制する物質が含まれています. この天然の阻害剤はサメに豊富に存在し,彼らの腫瘍の希少性を説明する可能性がある.
科学分野:
- バイオケミストリー バイオケミストリー
- 腫瘍学 腫瘍学
- マリン・バイオロジー マリン・バイオロジー
背景:
- 固体腫瘍は,成長のために新しい血管 (血管新生) を必要とします.
- 哺乳類の軟骨には限られた抗血管新生性があります.
研究 の 目的:
- サメの軟骨の血管新生抑制特性を調査する.
- 抗がん剤の源としてサメの軟骨の潜在能力を特定する.
主な方法:
- 阻害物質に対するサメの軟骨の分析.
- 腫瘍の成長と血管新生に関するインビトロおよびインビボ研究.
主要な成果:
- サメの軟骨には,血管新生の強力な阻害剤が含まれています.
- この要因は,実験モデルにおける腫瘍の成長を著しく制限する.
- サメは自然に発生する腫瘍の発生率が低い.
結論:
- サメの軟骨は,自然に発生する抗血管新生因子の豊富な源です.
- この因子は,腫瘍の血管化を阻害することによって,がん治療の可能性を秘めています.
- 抗血管新生性の性質は,サメで観察される低がん率に寄与する可能性があります.
関連する概念動画
The Tumor Microenvironment
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Mechanism of Angiogenesis
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...


